France sees no reason to suspend AstraZeneca shot, minister says
Reuters
Published Mar 11, 2021 01:38PM ET
PARIS (Reuters) - French health authorities see no reason to suspend the use of AstraZeneca (NASDAQ:AZN) COVID-19 vaccinations, despite suspensions in some other European countries, French Health Minister Olivier Veran said on Thursday.
Health authorities in Denmark, Norway and Iceland on Thursday suspended the use of AstraZeneca's shot following reports of the formation of blood clots in some people who had been vaccinated.
Veran said the French drug safety agency, in line with its European Union counterpart, had advised that there was no reason to suspend injections with the AstraZeneca vaccine.
"The benefits of the AstraZeneca vaccine are considered higher than the risks at this point," Veran said at the government's weekly coronavirus briefing.
He said investigations were continuing in France and abroad and added that Britain - which has vaccinated millions with the AstraZeneca shot - advised continuing with it and had not noted large-scale excess risk related to the vaccine.
Veran, who is a neurologist, said that for about five million Europeans vaccinated with AstraZeneca, only about 30 people have experienced blood coagulation problems, which is in line with the number of cases one would expect for five million people who had not been vaccinated.
"We are looking systematically at each declared case of undesired serious side-effects ... each case is analysed for a link of causality with the vaccination, which so far has not been formally identified," Veran said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.